Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can brain training rewire the MS brain? study probes cognitive decline

NCT ID NCT04806568

NEW Symptom relief Sponsor: Aristotle University Of Thessaloniki Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether a 12-week computerized cognitive training program can improve thinking and change brain activity in people with multiple sclerosis. The study enrolls 180 adults with MS who have mild to moderate disability. Participants train for one hour a day, three days a week, using a tablet-based program that targets speed, attention, working memory, and executive function. The researchers measure changes in brain electrical activity and connectivity using EEG, along with tests of thinking and daily function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
computerized cognitive training (BrainHQ)
What this could lead to
If it works, this could offer a non-drug way to help people with multiple sclerosis manage thinking problems and guide how brain training is designed.
What could go wrong
The trial is small and measures brain activity changes, not whether thinking improves in daily life. Brain training may not produce lasting benefits, and participants must commit to an hour of training three days a week for 12 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for people with MS: * Male/female patients aged 18 to 65 years at screening * Diagnosis of MS according to the 2017 Revised McDonald criteria * Disability status at screening with an EDSS score of 0 to 6.5 * Relapsing MS and progressive MS as defined by Lublin * Neurologically stable within 1 month prior to screening * Patients receiving the same Disease Modifying Treatment (DMT) for at least 6 months Exclusion Criteria for people with MS: * Patients suspected of not being able or willing to cooperate or comply with study protocol requirements * Patients meeting criteria for other demyelinating diseases of the CNS * Patients with active chronic disease (or stable but treated with immune therapy) of the immune system other than MS * Patients with any other significant CNS disease or serious psychiatric disorder which can interfere with the patient's ability to cooperate or comply with the study procedure * Patients unable or unwilling to undergo MRI scans and EEG Inclusion Criteria for Healthy Controls: • Normal hearing and normal or corrected-to-normal vision Exclusion Criteria for Healthy Controls: * Any diagnosed neurological, mental, developmental, or psychiatric disorder * Unrecovered neurological disorders (i.e., stroke, traumatic brain injury) * Unstable medication within the last 3 months * Intake of central nervous drugs (e.g., antidepressants) * Severe physical disorder * Concurrent participation in another relevant study * Patients unable or unwilling to undergo EEG measurements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive decline Multiple sclerosis

Contacts and locations

Locations

  • Laboratory of Medical Physics and Digital Innovation, AUTH

    Thessaloniki, Central Macedonia, 54124, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.